扁桃体来源间充质干细胞在组织再生中的应用:简要综述。
Application of Tonsil-Derived Mesenchymal Stem Cells in Tissue Regeneration: Concise Review.
机构信息
Department of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.
Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.
出版信息
Stem Cells. 2019 Oct;37(10):1252-1260. doi: 10.1002/stem.3058. Epub 2019 Jul 25.
Since the discovery of stem cells and multipotency characteristics of mesenchymal stem cells (MSCs), there has been tremendous development in regenerative medicine. MSCs derived from bone marrow have been widely used in various research applications, yet there are limitations such as invasiveness of obtaining samples, low yield and proliferation rate, and questions regarding their practicality in clinical applications. Some have suggested that MSCs from other sources, specifically those derived from palatine tonsil tissues, that is, tonsil-derived MSCs (TMSCs), could be considered as a new potential therapeutic tool in regenerative medicine due to their superior proliferation rate and differentiation capabilities with low immunogenicity and ease of obtaining. Several studies have determined that TMSCs have differentiation potential not only into the mesodermal lineage but also into the endodermal as well as ectodermal lineages, expanding their potential usage and placing them as an appealing option to consider for future studies in regenerative medicine. In this review, the differentiation capacities of TMSCs and their therapeutic competencies from past studies are addressed. Stem Cells 2019;37:1252-1260.
自从发现干细胞和间充质干细胞(MSCs)的多能性特征以来,再生医学有了巨大的发展。源自骨髓的 MSCs 已广泛应用于各种研究应用中,但存在一些局限性,如获取样本的侵袭性、低产量和增殖率,以及其在临床应用中的实用性问题。有人认为,源自其他来源的 MSCs,特别是源自腭扁桃体组织的 MSCs(TMSCs),由于其增殖率较高、分化能力较强、免疫原性较低且易于获取,可以被视为再生医学中一种新的潜在治疗工具。有几项研究已经确定 TMSCs 不仅具有向中胚层谱系分化的潜能,而且还具有向内胚层和外胚层谱系分化的潜能,从而扩大了它们的潜在用途,并将其作为再生医学未来研究中令人感兴趣的选择。在这篇综述中,讨论了 TMSCs 的分化能力及其过去研究中的治疗能力。干细胞 2019;37:1252-1260。
相似文献
Cell Death Dis. 2018-2-7
Stem Cells Transl Med. 2015-10
Endocr Metab Immune Disord Drug Targets. 2018
Tissue Eng Regen Med. 2021-4
引用本文的文献
Front Bioeng Biotechnol. 2025-8-22
Tissue Eng Regen Med. 2025-9-3
Genes (Basel). 2024-12-19
本文引用的文献
Tissue Eng Regen Med. 2018-10-19
Tissue Eng Regen Med. 2016-4-5
Front Med (Lausanne). 2018-6-21
Cell Death Dis. 2018-2-7